MEDGm vs Embody
Both clinics sit in our top 10, so this page exists for readers already comparing them here. It is not written for search and is not submitted for indexing. Every figure below is read from the clinic's own page, with the date.
26 of the 51 clinics we rank are an affiliate partner. Scores come only from our published methodology. At equal displayed scores, active affiliate partners are listed first. What it changes is which clinic a promoted button points at, and every such link carries a PICK badge in the table so you can see it before you click.
PickPublishes every plan length with its total billed and its per-month rate on each product page, and covers more routes than any clinic here. But the $169/mo headline is $2,028 charged up front and non-refundable.
from $169/mo on a $2,028 prepaid year
Verified 2026-09-16
Visit →Affiliate link
| MEDGm | Embody | |
|---|---|---|
| Price | from $169/mo on a $2,028 prepaid yearTheir page, read 2026-09-16 | from $79/mo for a one-month supply (sale price)Their page, read 2026-09-14 |
| Price shape | one-ongoing-rate | not-verified |
| What the price doesn’t say | $169/mo only exists on the 12-month plan, and the $2,028 is charged up front and non-refundable. Month to month is $299, or $179 for a first month with the published code. | This price depends on which link you arrive through, so treat no single number as the price. Our affiliate link resolves to a countdown-gated $69/mo intro that steps up after the first month; Embody's own public homepage shows $79, and a direct visit has shown $99. |
| What it covers | 12 months of compounded semaglutide at any dose, labs and metabolic report, provider consultation, dose adjustments, side-effect medications and shippingTheir page, read 2026-09-16 | Not published. The page does not say what the figure covers.Their page, read 2026-09-14 |
| Billed on top | Nothing on the compounded plans. Labs, shipping and side-effect medication are included. On the three brand-name routes the published figure is a membership only ($99 Zepbound/Wegovy, $171 Ozempic) and the medication cost is not published.Their page, read 2026-09-16 | Not recorded. We have not found a statement either way.Their page, read 2026-09-14 |
| Commitment | Committed term. The rate applies on a $2,028 prepaid year. Billed up front on that term. What happens after the first period: Publishes a full term grid with the first month priced separately: "$597 → $199/mo billed every 3 months", "$1,134 → $189/mo billed every 6 months", "$2,028 → $169/mo billed every 12 months", alongside "First month $179". The ongoing rate is the tier, and the entry price is labelled as the entry price. (Read at source 2026-09-18.).Their page, read 2026-09-16 | Committed term. The rate applies for a one-month supply (sale price). What happens after the first period: The ongoing cost is the 12-month tier at $149/mo; the cheap headline is the first-month figure.Their page, read 2026-09-14 |
| Routes | compounded semaglutide, compounded tirzepatide, compounded semaglutide tablet, brand-name Zepbound, brand-name Wegovy pill, brand-name Wegovy pen, brand-name Ozempic | compounded semaglutide, compounded tirzepatide, oral (gum) |
| Score | 7.9 | 7.2 |
What is on the record
Documented findings, each with its source and date on the clinic’s review page. An FDA warning letter is an allegation by the agency, not a court ruling.
MEDGm
Nothing documented in what we check.
Embody
- Two storefronts, one companyEmbody and SnagRx are the same company
- Our link's price is not the public priceEmbody shows a different price on our link than in public
- The full record, with dates
What one does that the other doesn’t
MEDGm
Offers brand-name where Embody does not.
Embody
Nothing MEDGm does not also offer, on the routes we record.
Who each one suits
Every line below is a difference we can measure, with the field or criterion it comes from. Where a side is empty, nothing in what we record favours it. We would rather say that than invent a reason.
MEDGm
- The two entry figures are not comparable: Embody's rises after the first period.Basis: published price terms (introductory rate)
- Only one of the two offering: brand-name.Basis: published treatments, by drug and route
- Scores clearly higher on clinical (8.5 vs 7.5).Basis: our published scoring rubric
- Scores clearly higher on transparency (7.5 vs 5.0).Basis: our published scoring rubric
Embody
- Scores clearly higher on pricing (8.5 vs 7.0).Basis: our published scoring rubric
- Its figure is not confirmed. Treat the comparison above as provisional on this side.Basis: price confirmation status